I
Ibex Medical Analytics
Pioneers AI-based cancer diagnostics in pathology
About Ibex Medical Analytics
Ibex AI is a leading startup in the healthcare technology sector, specializing in artificial intelligence (AI)-powered diagnostic solutions for cancer care. The company's primary focus is to assist pathologists in providing better cancer care to patients globally. Ibex AI's products are designed by pathologists for pathologists, ensuring a deep understanding of the needs and challenges in the field.
Read full description
The company operates in the healthcare technology market, serving a clientele that includes top physicians, health systems, and diagnostic solution providers worldwide. Ibex AI's business model revolves around its AI-powered diagnostic platform, which is capable of detecting cancer and over a hundred other diagnostic features in various tissue types. The platform's accuracy and efficiency are clinically proven, and it offers an improved user experience.
Ibex AI's AI algorithms are developed from rich datasets extracted from over 10 million slides from multiple pathology institutes. These algorithms are trained by teams of expert pathologists using deep learning technologies, a type of AI that mimics the human brain's learning process.
The company recently raised $55 million in Series C funding to drive global adoption of AI for cancer diagnosis. The funding round was led by 83NORTH and included Sienna Venture Capital and existing investors Octopus Ventures, aMoon Fund, Planven Entrepreneur Ventures, and Dell Technologies Capital.
In terms of revenue, Ibex AI makes money by selling its AI-powered diagnostic solutions to healthcare providers and diagnostic solution providers. The company's recent funding suggests a strong market interest and potential for growth in the AI healthcare technology sector.
At a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Tel Aviv-Yafo, Israel
- Employees
- 97
- Open positions
- 2
- Dealroom signal
- 69.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Analytics, Biotechnology, Oncology, Pathology, Medical Imaging, Core AI, Health Diagnostics
- Technology
- Artificial Intelligence, Deep Tech, Machine Learning
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Sep 2023 | $55M | $220M | Planven Investments · Dell Technologies Capital · Octopus Ventures · aMoon Fund | ↗ |
| GRANTOther financing | Mar 2023 | $2M | — | NHS England | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Ibex Medical Analytics is 15K monthly website visits, down 16.7% over the last three months. Ibex Medical Analytics's team declined 6.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
NHS England
Series A5 investors entered at this stage
aMoon Fund
Kamet Ventures
83North
Dell Technologies Capital
Octopus Ventures
Series B and later3 investors entered at this stage
Kreos Capital
Planven Investments
Sienna Investment Managers
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ibex Medical Analytics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ibex Medical Analytics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.